Silence Therapeutics plc Share Price & Technical Analysis
SLN · $6.37 (-2.45%)
Healthcare / Biotechnology
$6.37
-2.45%
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated …
Price chart
Seasonality
Jun has 1 positive and 3 negative years (last 5 years shown)
-6% return in Jun, -4% avg return in past 3 year Jun month.
16% return in 2026, 12% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -23% | 13% | 0% | 38% | -5% | -6% | – | – | – | – | – | – | 16% |
| 25 | -24% | -12% | -38% | 32% | 57% | -2% | 5% | -21% | 6% | 38% | -7% | -8% | 27% |
| 24 | 28% | 12% | -15% | 3% | -5% | -9% | 9% | -7% | -6% | -4% | -55% | -13% | -62% |
| 23 | -13% | -9% | -47% | 10% | -23% | 0% | 9% | 53% | 10% | -32% | 82% | 32% | 72% |
| 22 | -12% | -9% | 3% | -35% | -28% | 24% | -11% | -1% | -2% | 12% | 34% | -5% | -31% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Divesiran (SLN124), which is in Phase 2 development for polycythemia vera, and SLN548 for complement-mediated renal diseases. It also develops Zerlasiran (SLN360) for cardiovascular disease associated with elevated lipoprotein(a); SLN312 for dyslipidemia; SLN365 for hypercholesterolemia; and SLN098 for obesity. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, United Kingdom.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$307.97M
P/E ratio
—
52W high
$8.40
52W low
$4.19
Volume
1,89,729
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹34,400
Abbott Laboratories Cede…
₹32,740
Eli Lilly And Company Ce…
₹28,720
Unitedhealth Group Inc C…
₹17,140
Elevance Health Inc
₹6,770
Frequently asked questions
- What is Silence Therapeutics plc share price today?
- Silence Therapeutics plc (SLN) last traded around $6.37 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does SLN have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for SLN. Download the app for real-time alerts.
- How can I analyze Silence Therapeutics plc stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.